首页> 美国卫生研究院文献>Neuropsychiatric Disease and Treatment >Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada

【2h】

Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada

机译：利培酮长效注射剂治疗精神分裂症：加拿大电子精神分裂症治疗依从性注册系统的24个月结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveTo assess outcomes over 24 months in Canadian patients with schizophrenia initiated on risperidone long-acting injection (RLAI) and participating in the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

机译：目的评估使用利培酮长效注射剂（RLAI）并参加电子精神分裂症治疗依从性注册（e-STAR）的加拿大精神分裂症患者在24个月内的结局。

著录项

期刊名称 Neuropsychiatric Disease and Treatment
作者
Richard Williams; Ranjith Chandrasena; Linda Beauclair; Doanh Luong; Annette Lam;
展开▼
作者单位

展开▼
年(卷),期 2014(10),-1
年度 2014
页码 417–425
总页数 9
原文格式 PDF
正文语种
中图分类神经病学;精神病学;
关键词
schizophrenia Canada risperidone long-acting injection e-STAR;

机译：加拿大精神分裂症;利培酮长效注射剂;e-STAR;

相似文献

外文文献
中文文献
专利

1. Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada [J] . Richard Williams, Ranjith Chandrasena, Linda Beauclair, Neuropsychiatric Disease and Treatment . 2014,第1期

机译：利培酮长效注射剂治疗精神分裂症：加拿大电子精神分裂症治疗依从性注册系统的24个月结果
2. Treatment retention with risperidone long-acting injection: 24-month results from the electronic schizophrenia treatment adherence registry (e-STAR) in six countries [J] . PeuskensJ., OlivaresJ.M., PecenakJ., Current medical research and opinion . 2010,第3期

机译：利培酮长效注射剂的治疗保留：六个国家电子精神分裂症治疗依从性登记系统（e-STAR）的24个月结果
3. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). [J] . Olivares JM, Rodriguez Morales A, Diels J European psychiatry: the journal of the Association of European Psychiatrists . 2009,第5期

机译：西班牙使用利培酮长效注射剂或口服抗精神病药治疗的精神分裂症患者的长期预后：电子精神分裂症治疗依从性登记系统（e-STAR）的结果。
4. Predicting Adherence to Treatment for Schizophrenia from Dialogue Transcripts [C] . Christine Howes, Matthew Purver, Rose McCabe, Annual meeting of the Special Interest Group on Discourse and Dialogue . 2012

机译：从对话记录中预测对精神分裂症治疗的依从性
5. Introducing Risperidone for Treatment of Schizophrenia to the Essential Drug List in Uganda: A Budget Impact Analysis [D] . Liu, Rong. 2017

机译：在乌干达将利培酮引入治疗精神分裂症的基本药物目录：预算影响分析
6. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America [O] . Rogelio Apiquian, Rodrigo Córdoba, Mario Louzã 2011

机译：长效注射利培酮在精神分裂症患者中的临床结果：拉丁美洲电子精神分裂症治疗依从性登记处的六个月随访
7. Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada [O] . Annette Lam, Richard Williams, Ranjith Chandrasena, 2014

机译：Risperidone长效注射治疗精神分裂症：24个月的电子精神分裂症治疗依从性登记处在加拿大的结果

Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada

摘要

著录项

相似文献

相关主题

期刊订阅